This post has been de-listed
It is no longer included in search results and normal feeds (front page, hot posts, subreddit posts, etc). It remains visible only via the author's post history.
Hey everyone I keep seeing a lot of talk about a buyout and I know that’s what Attosa is interested in if everything goes well with the current on going studies. I was just curious what people’s thoughts were realistically on a BO price based on the current market and value. Thanks! I’d be happy with 10-20.
I try to be realistic and conservative in my BO estimates, so this is what I’ve got:
Tamoxifen is currently earning 680M/year. If Endoxifen replaces Tamoxifen, with a multiplier of 8x (I believe industry average is 12ish), that puts the value of Atossa at ~5.4 billion. Rounding down to 5B flat (conservative), divided by 126M shares gets us to roughly $40 pps.
So my BO target is $40.
The only reason I could imagine it not getting approved is if AstraZeneca (owners of tamoxifen) pays off the FDA.
Frankly I’m annoyed that trials are even necessary. The liver metabolizes tamoxifen (current standard of care) into Endoxifen, so it’s certainly not dangerous or ineffective. ATOS has a patent on a much more efficient version of what people already take, yet it languishes in trials, ugh.
Nothing would change, other than maybe the ticker symbol. The shares would still trade, just not on the nasdaq.
Subreddit
Post Details
- Posted
- 1 year ago
- Reddit URL
- View post on reddit.com
- External URL
- reddit.com/r/AtossaThera...
Personally I don’t see the point in devaluing the company just to stay on the Nasdaq. If Endox succeeds in the trials, it won’t matter where it’s traded. A buyout is a buyout.